Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233880 | 0.90 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL658863 | 0.88 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2TSHRALDH1A1 | |
| Nitric Acid SCHEMBL2075754 | 0.85 | MAPT (0.64) | NPC1RAB9AALDH1A1GAAPOLB | |
| Nitric Acid SCHEMBL1363345 | 0.84 | MAPT (0.57) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| Nitric Acid SCHEMBL27217371 | 0.82 | RAB9A (0.55) | RAB9ASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL1430921 | 0.79 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2TSHRGAA | |
| Nitric Acid SCHEMBL2073517 | 0.79 | MAPT (0.54) | SMN1; SMN2TSHRALDH1A1GAANPSR1 | |
| SCHEMBL12727668 | 0.77 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL3613703 | 0.76 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2TSHRALDH1A1 | |
| Nitric Acid SCHEMBL6991286 | 0.76 | ADRA2C (0.66) | SIRT6NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| EP-1567522-B1 | PYRIMIDINE COMPOUNDS | CYCLACEL LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
| EP-1567522-A1 | PYRIMIDINE COMPOUNDS | Cyclacel Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005052147-A2 | METHOD OF SCREENING FOR A MODULATOR OF CDK4 | CYCLACEL LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| EP-0989985-B1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-11-05 | — | — | EP | disclosed |
| US-6133257-A | Fused polycyclic 2-aminopyrimidine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-10-17 | — | — | US | disclosed |
| EP-0989985-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-04-05 | — | — | EP | disclosed |
| WO-1998058926-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | SIRT6 1574/4885NPC1 3230/4885RAB9A 3043/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | SIRT6 1574/4885NPC1 3230/4885RAB9A 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.